Results 1 to 10 of about 761 (100)

Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis [PDF]

Journal of Comparative Effectiveness Research
Aim: Etrasimod and ozanimod are selective sphingosine 1-phosphate receptor modulators targeting the S1P1,4,5, and S1P1,5 receptors, respectively, for the treatment of patients with moderately to severely active ulcerative colitis (UC).
Joseph Cappelleri, Karolina Wosik, Peter Hur   +2 more
exaly   +4 more sources

Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis—EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol [PDF]

BMJ Open
Introduction Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC).
Peter M Irving, Gordon W Moran, Michael McLean, Alissa Walsh, Maria Kudela, Ulf Helwig, Robert Battat, Burak Sahin, Shellie J Radford, Elke Binder, Nataliia Kulchytska   +10 more
doaj   +4 more sources

The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program [PDF]

Therapeutic Advances in Gastroenterology
Background: Many patients show inadequate response or intolerance to conventional therapies for ulcerative colitis (UC), including 5-aminosalicylates (5-ASA), thiopurines, and corticosteroids (CS).
David T. Rubin, Charlie W. Lees, Filip Baert, Maria Kudela, Abhishek Bhattacharjee, Krisztina Lazin, Martina Goetsch, Arcangelo M. Abbatemarco, Karolina Wosik, John K. Marshall   +9 more
doaj   +3 more sources

Safety evaluation of etrasimod for ulcerative colitis based on the FAERS database [PDF]

Scientific Reports
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator that selectively activates S1P receptor subtypes 1, 4, and 5, but exhibits no detectable activity on S1P2 and S1P3. It is primarily used for the treatment of ulcerative colitis (UC).
Qian Guo, Meirong Shan, Wei Gao
exaly   +3 more sources

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod [PDF]

Frontiers in Pharmacology
ObjectiveTo characterize the post-marketing safety profile of etrasimod using the latest data from the FDA Adverse Event Reporting System (FAERS), and to provide a comparative analysis versus other sphingosine-1-phosphate (S1P) receptor modulators ...
Huibiao Li
exaly   +4 more sources

Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme [PDF]

BMJ Open Gastroenterology
Objective Bothersome ulcerative colitis (UC) symptoms include stool frequency (SF), rectal bleeding (RB), abdominal pain and bowel urgency; symptomatic relief is a key treatment goal.
Peter M Irving, Remo Panaccione, Joseph Wu, Bruce E Sands, Marla C Dubinsky, John C Woolcott, Wenjin Wang, Maria Chaparro, Martina Goetsch, Lauren Bartolome, Karolina Wosik, Eugenia Kunina, Christina Cognata   +12 more
doaj   +2 more sources

Sphingosine-1-phosphate receptor modulators in ulcerative colitis – a narrative review of current evidence and practical considerations [PDF]

Drugs in Context
Ulcerative colitis (UC) is a chronic inflammatory bowel disorder with a relapsing and remitting course often necessitating the use of advanced therapy to maintain disease control. Sphingosine-1-phosphate receptor modulators (S1PRMs) represent a new class
Anish J Kuriakose Kuzhiyanjal, Karishma Sethi-Arora, Gaurav B Nigam, Jimmy K Limdi   +3 more
doaj   +2 more sources

Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study [PDF]

Frontiers in Pharmacology
ObjectivesEtrasimod is an investigational, oral, once-daily, selective S1P1,4,5 receptor modulator in development for the treatment of immune-mediated inflammatory diseases. We present safety, tolerability, pharmacokinetic, and pharmacodynamic results of
Fangfang Wang, Xiaoye Niu, Na Liu, Zhengying Zhu, Yun Lin, Lisa Ying, Haiyan Li   +6 more
doaj   +2 more sources

Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study [PDF]

Intestinal Research
Background/Aims Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC).
Ken Takeuchi, Hiroshi Nakase, Tadakazu Hisamatsu, Katsuyoshi Matsuoka, Shoko Arai, Hirotoshi Yuasa, Motoki Oe, Ryosuke Ono, Michael Keating, Guibao Gu, Krisztina Lazin, Aoibhinn McDonnell, Koki Fukuta, Toshifumi Hibi   +13 more
doaj   +2 more sources

Advancements in ulcerative colitis management: A critical assessment of etrasimod therapy

Health Sciences Review
Ulcerative Colitis (UC) is a persistent inflammatory condition of the colon that occurs due to the disruption in the epithelial barrier and immunological responses.
Pooja Chawla, Rabin Debnath
exaly   +3 more sources